Skip to main content
. 2024 Mar 12;25(6):3222. doi: 10.3390/ijms25063222

Figure 3.

Figure 3

Drug–drug interactions between ART and cytotoxic agents according to Medscape, Liverpool University, and PEPID interaction checkers’ reports. Legend: no interaction expected (green); potential weak interaction (yellow); potential interaction (orange); do not co-administer (red). ANTRA: anthracyclines; CTX: cyclophosphamide; ERI: eribulin; GEM: gemcitabine; MTX: methotrexate; PT: platinum salts; TXN: taxanes; VNB: vinorelbine; 5FU: 5-fluorouracil; NNRTIs: non-nucleoside reverse transcriptase inhibitors; NRTIs: nucleoside reverse transcriptase inhibitors; PIs: protease inhibitors; ABC: abacavir; ABT: albuvirtide; ATV: atazanavir; AZT: zidovudine; BIC: bictegravir; CAB: cabotegravir; c: cobicistat; DPV: dapivirine; DRV: darunavir; DOR: doravirine; DTG: dolutegravir; EFV: efavirenz; ENF: enfuvirtide; EVG: elvitegravir; ETR: etravirine; FTC: emtricitabine; FTR: fostemsavir; IBA: ibalizumab-uiyk; MVC: maraviroc; NVP: nevirapine; RAL: raltegravir; RPV: rilpivirine; RTV/r: ritonavir; TAF: tenofovir alafenamide; TDF: tenofovir-disoproxil fumarate; 3TC: lamivudine.